The latest price target for Lipella Pharmaceuticals (NASDAQ:LIPO) was reported by Maxim Group on April 9, 2024. The analyst firm set a price target for $2.00 expecting LIPO to fall to within 12 months (a possible -19.35% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Lipella Pharmaceuticals (NASDAQ:LIPO) was provided by Maxim Group, and Lipella Pharmaceuticals initiated their buy rating.

There is no last upgrade for Lipella Pharmaceuticals

There is no last downgrade for Lipella Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lipella Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lipella Pharmaceuticals was filed on April 9, 2024 so you should expect the next rating to be made available sometime around April 9, 2025.

While ratings are subjective and will change, the latest Lipella Pharmaceuticals (LIPO) rating was a initiated with a price target of $0.00 to $2.00. The current price Lipella Pharmaceuticals (LIPO) is trading at is $2.48, which is out of the analyst’s predicted range.